Nobilis Therapeutics is a pioneering brand dedicated to bringing groundbreaking treatments to patients suffering from psychiatric and neurodegenerative diseases. With a focus on utilizing the unique properties and biological effects of noble gases, Nobilis Therapeutics aims to provide innovative therapeutic solutions for conditions such as PTSD, Autism, and Dementia. As part of their mission, Nobilis Therapeutics has developed a revolutionary portable inhalation device, the Zephyrus™, which allows for safe and self-administration of their proprietary therapeutic NBTX-001.

This device, combined with a streamlined and accelerated pathway of clinical development, ensures that patients receive efficient and effective treatment options. Founded by a team consisting of a drug developer, scientist, and a pioneer in medical gas research, Nobilis Therapeutics has quickly gained recognition and accomplished significant milestones. They have secured an exclusive licensing agreement with Harvard University for the use of NBTX-001 in treating PTSD, filed 10 patents, and are poised to initiate two clinical trials in the near future.

With a premier scientific advisory board guiding their clinical development strategy, Nobilis Therapeutics is at the forefront of innovative therapies for psychiatric and neurodegenerative diseases